Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5009507 | 0.72 | AKR1C3 (0.54) | AKR1C3AKR1C1SIGMAR1SLC18A3AGTR2 | |
| SCHEMBL5007409 | 0.70 | AKR1C3 (0.51) | AKR1C3AKR1C1AGTR2 | |
| SCHEMBL444560 | 0.68 | AKR1C3 (0.56) | HRH3AKR1C3AKR1C1SIGMAR1SLC18A3 | |
| SCHEMBL9294538 | 0.68 | CHRNB2 (0.53) | AKR1C3AKR1C1 | |
| SCHEMBL9294528 | 0.68 | CHRNB2 (0.53) | AKR1C3AKR1C1 | |
| SCHEMBL9294533 | 0.68 | CHRNB2 (0.53) | AKR1C3AKR1C1 | |
| SCHEMBL18711267 | 0.67 | SLC18A3 (0.50) | AKR1C3AKR1C1SIGMAR1SLC18A3 | |
| SCHEMBL1587410 | 0.67 | AKR1C3 (0.54) | AKR1C3AKR1C1SLC18A3AGTR2 | |
| SCHEMBL23124105 | 0.66 | SLC18A3 (0.53) | HRH3AKR1C3AKR1C1SIGMAR1SLC18A3 | |
| SCHEMBL17292430 | 0.66 | AKR1C3 (0.72) | AKR1C3AKR1C1FFAR4SIGMAR1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | HRH3 194/4885AKR1C3 1826/4885AKR1C1 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.